PIRS — Pieris Pharmaceuticals Share Price
- $9.57m
- -$9.51m
- $42.81m
- 28
- 88
- 20
- 42
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.55 | ||
Price to Tang. Book | 0.55 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.29 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -89% | ||
Return on Equity | -86.86% | ||
Operating Margin | -47.76% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 46.28 | 29.32 | 31.42 | 25.9 | 42.81 | 6.63 | n/a | 8.03% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
Directors
- James Geraghty NEC (67)
- Stephen Yoder PRE (45)
- Thomas Bures CFO (47)
- Hitto Kaufmann SVP (50)
- Ahmed Mousa SVP (37)
- Tim Demuth SVP
- Shane Olwill SVP
- Ann Barbier IND (57)
- Peter Kiener IND (69)
- Christopher Kiritsy IND (56)
- Michael Richman IND (60)
- Maya Said IND (44)
- Matthew Sherman IND (65)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 24th, 2013
- Public Since
- December 18th, 2014
- No. of Shareholders
- 31
- No. of Employees
- 46
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,320,240
- Address
- 225 Franklin Street, 26Th Floor, BOSTON, 02110
- Web
- https://www.pieris.com/
- Phone
- +1 8572468998
- Auditors
- Ernst & Young LLP
Upcoming Events for PIRS
Q3 2024 Pieris Pharmaceuticals Inc Earnings Release
Similar to PIRS
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 22:39 UTC, shares in Pieris Pharmaceuticals are trading at $9.09. This share price information is delayed by 15 minutes.
Shares in Pieris Pharmaceuticals last closed at $9.09 and the price had moved by -48.47% over the past 365 days. In terms of relative price strength the Pieris Pharmaceuticals share price has underperformed the S&P500 Index by -59% over the past year.
The overall consensus recommendation for Pieris Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Pieris Pharmaceuticals does not currently pay a dividend.
Pieris Pharmaceuticals does not currently pay a dividend.
Pieris Pharmaceuticals does not currently pay a dividend.
To buy shares in Pieris Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $9.09, shares in Pieris Pharmaceuticals had a market capitalisation of $12.00m.
Here are the trading details for Pieris Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PIRS
Based on an overall assessment of its quality, value and momentum Pieris Pharmaceuticals is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pieris Pharmaceuticals is $7.00. That is 22.99% below the last closing price of $9.09.
Analysts covering Pieris Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.20 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pieris Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -37%.
As of the last closing price of $9.09, shares in Pieris Pharmaceuticals were trading -41.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pieris Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pieris Pharmaceuticals' management team is headed by:
- James Geraghty - NEC
- Stephen Yoder - PRE
- Thomas Bures - CFO
- Hitto Kaufmann - SVP
- Ahmed Mousa - SVP
- Tim Demuth - SVP
- Shane Olwill - SVP
- Ann Barbier - IND
- Peter Kiener - IND
- Christopher Kiritsy - IND
- Michael Richman - IND
- Maya Said - IND
- Matthew Sherman - IND